Takeda Expands Oncology Research, Demonstrating Commitment to Patient Community at 15th International Symposium on Myelodysplastic Syndromes

Thursday, May 9, 11:45 a.m. 12:45 p.m. (Tivoli Congress Hall).

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Tuesday, May 7, 2019
Information
Tags: 
Health, Biotechnology, Oncology, Pharmaceutical, International Prognostic Scoring System, RTT, Myelodysplastic syndrome, Clinical medicine, Chronic myelomonocytic leukemia
Geotags: 
United States, Europe, DENMARK, Massachusetts, Japan
⚠generated by AI ↴
Summary
Key Points: 
  • Thursday, May 9, 11:45 a.m. 12:45 p.m. (Tivoli Congress Hall).
  • There are several classifications of MDS lower risk to higher-risk determined by blood counts, blast counts, mutations and cytogenetics.
  • Higher-risk disease is defined as intermediate, high or very high risk on the International Prognostic Scoring System Revised (IPSS-R), and these patients often have a poorer prognosis.
  • Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Neuroscience and Rare Diseases.


Takeda Pharmaceutical Company Limited [TSE:
4502 / NYSE: TAK] today announced that it will present a total
of five company-sponsored poster presentations, as well as an oral
pipeline symposium, at the 15th International Symposium on
Myelodysplastic Syndromes taking place in Copenhagen, Denmark from May
8-11, 2019. Takeda’s presentations will highlight the company’s
investigations into the epidemiology, prognosis and patient reported
outcomes for higher-risk myelodysplastic syndromes (HR-MDS) and the
related conditions – chronic myelomonocytic leukemia (CMML) and acute
myeloid leukemia (AML) – to achieve a deep understanding of these rare
cancers and the needs of this patient community.

“We are excited to join the MDS community at this upcoming meeting where
we will share key findings around Takeda’s research in HR-MDS, CMML and
AML,” said Hui Huang, PhD, Head, Oncology Global Outcomes Research at
Takeda. “For over a decade, there has been little advancement in
treatment options for people living with HR-MDS and CMML, despite poor
patient outcomes. Takeda’s investment in this wide-ranging global
outcomes research directly captures patient input to better understand
these cancers, as well as AML, and the impact on their lives. These
findings are an important aspect of our work as we strive to bring new
treatment options to patients.”

At this year’s International Symposium on Myelodysplastic Syndromes,
Takeda will present results from a variety of innovative research
studies. These results are the first global systematic review of HR-MDS
and CMML on incidence and prevalence, including the risk of
transformation to AML. The results will also quantify the disease
burden, discuss the difficulties associated with diagnosis and
underscore the significant unmet need of this patient population. Some
of this research was conducted in collaboration with the MDS Foundation
– an international non-profit advocacy organization whose mission is to
support and educate patients and healthcare providers with innovative
research into the fields of MDS, AML and related myeloid neoplasms.

Five Takeda Oncology-sponsored abstracts were accepted for poster
presentation, as well as an oral pipeline symposium during MDS 2019:

Note: All times listed are in Central European Standard Time

For more information, the MDS 2019 program is available here: https://mds.kenes.com/2019/scientific/scientific-program#.XJosUihKhdg

About Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and
Acute Myeloid Leukemia

Myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML)
and acute myeloid leukemia (AML) are rare forms of blood cancer that are
caused by irregular blood cell production within the bone marrow. As a
result of this irregular production, a person with MDS, CMML or AML does
not have enough normal red blood cells, white blood cells and/or
platelets in circulation. Symptoms for MDS, CMML and AML are often vague
and related to low blood counts, and may include fatigue, shortness of
breath, easy bruising or bleeding, loss of appetite, weakness, pale
skin, fever and frequent or severe infections.

There are several classifications of MDS – lower risk to higher-risk –
determined by blood counts, blast counts, mutations and cytogenetics.
Higher-risk disease is defined as intermediate, high or very high risk
on the International Prognostic Scoring System – Revised (IPSS-R), and
these patients often have a poorer prognosis. In some cases, MDS and
CMML can progress into AML.

About Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK)
is a global, values-based, R&D-driven biopharmaceutical leader
headquartered in Japan, committed to bringing Better Health and a
Brighter Future to patients by translating science into
highly-innovative medicines. Takeda focuses its R&D efforts on four
therapeutic areas: Oncology, Gastroenterology (GI), Neuroscience and
Rare Diseases. We also make targeted R&D investments in Plasma-Derived
Therapies and Vaccines. We are focusing on developing highly innovative
medicines that contribute to making a difference in people's lives by
advancing the frontier of new treatment options and leveraging our
enhanced collaborative R&D engine and capabilities to create a robust,
modality-diverse pipeline. Our employees are committed to improving
quality of life for patients and to working with our partners in health
care in approximately 80 countries and regions.

For more information, visit https://www.takeda.com

Copyright: 
Copyright Business Wire 2019